БУЙРАК ҲУЖАЙРАЛИ САРАТОН ЭКСТРАТУМОРАЛ МИКРОМУҲИТИ
##article.subject##:
цитотоксик Т-лимфоцитлар, иммунитетни назорат қилиш ингибитори, ўсманинг микро муҳити, мийелоид супрессор ҳужайралар, тартибга солувчи Т-ҳужайралар, буйрак ҳужайраси саратони, ўсма макрофаглари, қон томирлар эндотелийсиопооооорг ўсиш омили##article.abstract##
Ушбу шарҳ буйрак ҳужайраси саратони микро муҳитида таъсир кўрсатадиган иммуносупрессив механизмларни ўрганишга қаратилган. Ўсма ҳужайраларининг кўпайиши ва метастазига ёрдам берадиган ўсма ўсиш омилларини ўрганиш бўйича асосий адабиёт материаллари тўплами мавжуд, ўсимта микромухити ўсимта билан боғлиқ антигенларнинг иммунитет кузатувини чеклайди ва иммунитетни назарот қилиш пунктлари самарадорлигини чеклайди. Буйрак ҳужайралари саратони ммунитетни назорат қилиш ингибиторларига жавоб берадиган бир нечта ўсма турларидан бири бўлса-да, ушбу воситаларнинг самарадорлиги, MEV ўсма микро муҳитини ташкил этувчи суяк илигидаги турли хил ўсма инфилтрацияли мийелоид ҳужайралари билан чекланган бўлиши мумкин. Ушбу ҳужайраларнинг ўсма тўқималарида пайдо бўлишини йўқ қилишга ёки уларнинг иммуносупрессив функциясини зарарсизлантириш қаратилган бир қатор стратегиялар ҳайвонларнинг ўсмалари моделларида ва клиник тадқиқотларда далда берувчи натижалар кўрсатди.
Библиографические ссылки
Thorsson V., Gibbs D.L., Brown S.D., et al. The Immune Landscape of Cancer. // Immunity. 2018. 48(4). 812-830.
Rooney M.S., Shukla S.A., Wu C.J., et al. Molecular and genetic properties associated with local immune cytolytic activity. // Cell. 2015. 160. 48–61.
Senbabaoglu Y., Gejman R.S., Winer A.G., et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. // Genome Biol. 2016. 17. 231.
Motzer R.J., Tannir N.M., McDermott D.F., et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. // N Eng J Med. 2018. 378. 1277–90.
Samstein R.M., Lee C.H., Shoushtari A.N., et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. // Nat Genet. 2019. 51(2). 202-206.
Caldwell R.W., Rodriguez P.C., Toque H.A., et al. Arginase: A Multifaceted Enzyme Important in Health and Disease. // Physiol Rev. 2018. 98(2). 641-665.
Budhwar S., Verma P., Verma R., Rai S., Singh K. The yin and yang of myeloid-derived suppressor cells. // Front Immunol. 2018. 9. 2776.
Okada S.L., Simmons R.M., Franke-Welch S., et al. Conditioned media from the renal cell carcinoma cell line 786-O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype. // Cell Immunol. 2018. 323. 49–58.
Guan X., Liu Z., Zhang J., Jin X. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17, and IL-18 expression in blood and tumors. // Adv Clin Exp Med. 2018. 27. 947–953.
Najjar Y.G., Rayman P., Jia X., et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL-1β, IL8, CXCL5, and Mip-1α. // Clin Cancer Res. 2017. 23. 2346–2355.
Li J., Sun J., Li L., et al. HMGB1 promotes myeloid-derived suppressor cells and renal carcinoma immune escape. // Oncotarget. 2017. 8. 63290–63298.
Chevrier S., Crowell H.L., Zanotelli V.R.T., et al. Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry. // Cell Syst. – 2018. - 6(5). - 612-620.
Motoshima T., Miura Y., Wakigami N., et al. Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma. // Med Mol Morphol. 2018. 51. 57–63.
Chen Q., Wang J., Zhang Q., et al. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. // Br J Cancer. 2019. 121(9). 786-795.
Mei L., Shen C., Miao R., et al. RNA methyltransferase NSUN2 promotes gastric cancer cell proliferation by repressing p57(Kip2) by an m(5)C-dependent manner. // Cell Death Dis. 2020. 11(4). 270.
Karpel-Massler G., Nguyen T.T.T., Shang E., Siegelin M.D. Novel IDH1-Targeted Glioma Therapies. // CNS Drugs. 2019. 33(12). 1155-1166.
Mathew L.K., Lee S.S., Skuli N., et al. Restricted expression of miR-30c-2–3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF-2α activity. // Cancer Discovery. 2014. 4. 53–60.
Li B., Qui B., Walton Z.E., et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. // Nature. 2014. 513. 251–255.
Bellesoeur A., Carton E., Alexandre J., Goldwasser F., Huillard O. Axitinib in the treatment of renal cell carcinoma: design, development and place in therapy. // Drug Des Devel Ther. 2017. 11. 2801–2811.
Qian C-N. Hijacking the vasculature in ccRCC--co-option, remodelling and angiogenesis. // Nat Rev Urol. 2013. 10(5). 300-304.
Slater S.C., Jover E., Martello A., et al. MicroRNA-532-5p Regulates Pericyte Function by Targeting the Transcription Regulator BACH1 and Angiopoietin-1. // Mol Ther. 2018. 26(12). 2823-2837.
Wragg J.W., Finnity J.P., Anderson J.A., et al. MCAM and LAM4A are highly enriched in tumor blood vessels of renal cell carcinoma and predict patient outcome. // Cancer Res. 2016. 76. 2314–2326.
Klysz D., Tai X., Robert P.A., et al. Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. // Sci Signal. 2015. 8(396). ra97.
Steggerda S.M., Bennett M.K., Chen J., et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. // J Immunother Cancer. 2017. 5(1). 101.
Markowitz J., Wang J., Vangundy Z., et al. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. // Sci Rep. 2017. 7. 15424.
Geiger R., Rieckmann J.C., Wolf T., et al. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. // Cell. 2016. 167(3). 829-842.
Lee Y.C., Su Y.T., Liu T.Y., et al. L-Arginine and L-Citrulline Supplementation Have Different Programming Effect on Regulatory T-Cells Function of Infantile Rats. // Front Immunol. 2018. 9. 2911.
Hornyak L., Dobos N., Koncz G., et al. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. // Front Immunol. 2018. 9. 151.
Mitchell T.C., Hamid O., Smith D.C., et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: Phase I results from a multicenter, open-label phaseI/II trial (ECHO-202/ KEYNOTE-307). // J Clin Oncol. 2018. 36(32). 3223-3230.
Vijayan D., Young A., Teng M.W.L., Smyth M.J. Targeting immunosuppressive adenosine in cancer. // Nat Rev Cancer. 2017. 17. 7090–7024.
Weber R., Fleming V., Hu X., et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. // Front Immunol. 2018. 11. 1310.
Díaz-Montero C.M., Rini B.I., Finke J.H. The immunology of renal cell carcinoma. // Nat Rev Nephrol. 2020. doi: 10.1038/s41581-020-0316-3.
Gabrilovich D.I. Myeloid-Derived Suppressor Cells. // Cancer Immunol Res. 2017. 5(1). 3-8.
Orillion A., Hashimoto A., Damayanti N., et al. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal carcinoma. // Clin Cancer Res. 2017. 23. 5187–5201.
Liu J.F., Deng W.W., Chen L., et al. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer. // Mol Carcinog. 2018. 57. 429–439.
De Henau O., Rausch M., Winkler D., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. // Nature. 2016. 539. 443–447.
